GSTM1 and graft versus host disease: In a pharmacogenetic analysis on GST polymorphisms and HSCT outcome in a pediatric cohort of 69 HSCT patients, Ansari and coworkers found in a multivariate analysis that GSTM1-null subjects developed more GVHD (p = 0.03).